GlassScriptPhysician profile
Gabriel Hernandez
NPI 1164043782
$1,318.74
in general payments reported to CMS, 2019-2025
19 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $338 · 2023: $241 · 2024: $228 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $153.52 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Boston Scientific Corporation | $143.13 | 2022 | |
| Corcept Therapeutics | $134.78 | 2025 | Korlym |
| Madrigal Pharmaceuticals | $133.86 | 2024 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Intuitive Surgical, INC. | $90.32 | 2022-2023 | Da Vinci Surgical System |
| Amgen INC. | $88.36 | 2025 | Otezla, Repatha |
| Medtronic, INC. | $82.13 | 2022 | |
| Tandem Diabetes Care, INC. | $80.65 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $57.51 | 2022-2023 | Farxiga |
| Dexcom, INC. | $55.21 | 2024 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $42.12 | 2025 | Aptima |
| Novo Nordisk INC | $23.95 | 2025 | Wegovy |
| Lilly USA, LLC | $19.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.06 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.24 | 2022 | |
| Gilead Sciences, INC. | $17.85 | 2023 | Veklury |
| Astellas Pharma US INC | $17.49 | 2021 | |
| Abbvie INC. | $15.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.